Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Prostate cancer. Found 50 abstracts

no pagination
Sharma NK, Cohen RJ, Eade TN, Buyyounouski MK, Uzzo RG, Li JS, Crawford K, Chen DY, McNeeley S, Horwitz EM. An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy. Brachytherapy. 2010 Apr;9(2):126-30.   PMCID: not NIH funded
Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiotherapy and Oncology. 2010 Jul;96(1):6-12.   PMCID: Not required
Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating Tumor Cells: Evolving Evidence and Future Challenges. The oncologist. 2009 Jan;14(11):1070-82.   PMCID: not NIH funded
Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter M, Seider M. RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH-RISK PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2009 Jun;74(2):383-7.   PMCID: PMC2905150
Michalski JM, Roach M, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR. ACR Appropriateness Criteria (R) on External Beam Radiation Therapy Treatment Planning for Clinically Localed Prostate Cancer Expert Panel on Radiation Oncology-Prostate. International Journal of Radiation Oncology Biology Physics. 2009 Jul;74(3):667-72.
Zhang M, Ho A, Hammond EH, Suzuki Y, Bermudez RS, Lee RJ, Pilepich M, Shipley WU, Sandler H, Khor LY, Pollack A, Chakravarti A. Prognostic value of surviving in locally advanced prostate cancer: study based on RTOG 8610. International Journal of Radiation Oncology Biology Physics. 2009 Mar;73(4):1033-42.   PMCID: PMC 2678565
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02. European Urology. 2008 Oct;54(4):816-24.
Horwitz EM. Does addition of 6 months' androgen suppression to radiotherapy prolong survival of men with prostate cancer?. Nature Clinical Practice Urology. 2005 Jan;2(1):16-7.
Xiong W, Li J, Ma CM. Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer. Physics in Medicine and Biology. 2005 Jan;50(7):1483-92.
Hanks GE, Krall JM, Pilepich MV, Asbell SO, Perez CA, Rubin P, Sause WT, Doggett RL. Comparison of pathologic and clinical evaluation of lymph nodes in prostate cancer: Implications of RTOG data for patient management and trial design and stratification. International Journal of Radiation Oncology Biology Physics. 1992 Jan;23(2):293-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Prostate cancer

Prostate cancer prostate cancer Radiotherapy THERAPY TRIAL Radiation progression-free RANDOMIZED radiation-therapy migration SECONDARY ANALYSIS IRRADIATION quality prostate-cancer EXTRACAPSULAR EXTENSION duration BODY-COMPOSITION Dose escalation SPLICE VARIANTS local-control Lymph Node Excision patient care Fractionation lymph node antiandrogen epithelial-cells Androgen suppression Low-dose-rate brachytherapy CONFORMAL RADIOTHERAPY cancer radiotherapy PELVIC IRRADIATION SURVIVIN Patient treatment Gonadotropin-releasing hormone agonist Intraoperative planning Lymphography IMRT reduction embolization dosimetry alpha INTENSITY-MODULATED RADIOTHERAPY DEPRIVATION Time factor HORMONE AGONISTS Prostate IMMEDIATE Hormonal therapy Conformal radiotherapy postimplant trus images RADICAL PROSTATECTOMY Linear quadratic (LQ) model SUPPRESSION I-125 hypofractionation CARCINOMA RADICAL Radiation therapy Sleeved seeds MEN Tumors i-125 seeds External beam radiotherapy IN-VIVO Breast cancer resistant BONE-MINERAL DENSITY Target volume Patient variation Survivin predict survival Biological organs EXPRESSION conformality Survival NEOADJUVANT cancer beta ratio oncology colorectal-cancer Prostate-specific antigen carcinoma Dose fractionation EXTERNAL-BEAM RADIOTHERAPY tumor-control LYMPHADENECTOMY Circulating tumor cells oncology guidelines 3-DIMENSIONAL RADIOTHERAPY MESSENGER-RNA X-Ray Computed Tomography CLINICAL TARGET VOLUME Cardiovascular mortality Appropriateness criteria Parameter estimation RADIOTHERAPY Probability ANTI-APOPTOSIS GENE Linear equations prognostic value Clinical trial design peripheral-blood clinical-significance radiation dose fractionation protraction metastatic breast-cancer PROSTATECTOMY CELL-PROLIFERATION GASTRIC CARCINOMAS ANDROGEN SUPPRESSION PROTEIN HEPATOCELLULAR-CARCINOMA fractionation RECTAL BALLOON DOSE-VOLUME HISTOGRAMS implantation Prognostic factor Pelvic lymph nodes CONTROLLED-TRIAL Colon cancer polymerase-chain-reaction Lymph node evaluation ORGAN MOTION
Last updated on Friday, December 06, 2019